- Between 1990 and 2021, the number of people who had a new stroke (up by 70%), died from a stroke (up by 44%), and stroke-related health loss (up by 32%), has risen substantially worldwide.
- Stroke is highly preventable, with 84% of the stroke burden in 2021 attributable to 23 modifiable risk factors, including air pollution, excess body weight, high blood pressure, smoking, and physical inactivity—presenting a public health challenge and an opportunity for action.
- Notably, the contribution of high temperatures to poor health and early death due to stroke has risen 72% since 1990, a trend likely to increase in the future—underscoring the impact of environmental factors on the growing stroke burden.
- For the first time, the study reveals the high contribution (on a par with smoking) of particulate matter air pollution to subarachnoid haemorrhage (fatal brain bleed).
- Effective, accessible, and affordable measures to improve stroke surveillance, prevention (with the emphasis on managing blood pressure, lifestyle, and environmental factors), acute care, and rehabilitation need to be urgently implemented across all countries to reduce the stroke burden.
**For regional and individual-level country data, see Table 1 in the Article and appendix table 11**
Although stroke is highly preventable and treatable, there has been a rapid rise in the global stroke burden between 1990 and 2021, due to both population growth and the rise of aging populations worldwide, as well as a substantial increase in people’s exposure to environmental and behavioural risk factors. The findings of this major new analysis from the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) are published in The Lancet Neurology journal and being presented at the World Stroke Congress in Abu Dhabi in October 2024 [1].
Globally, the number of people having a new stroke rose to 11.9 million in 2021 (up by 70% since 1990), stroke survivors rose to 93.8 million (up by 86%), and stroke-related deaths rose to 7.3 million (up by 44%), making the condition the third leading cause of death worldwide (after ischaemic heart disease and COVID-19). More than three-quarters of those affected by strokes live in low- and middle-income countries (LMICs).
Additionally, estimates suggest that worldwide, the overall amount of disability, illness, and early death—a measurement known as disability-adjusted life years (DALYs)—lost to stroke increased by 32% between 1990 and 2021, rising from around 121.4 million years of healthy life lost in 1990 to 160.5 million years in 2021, making stroke the fourth leading cause of health loss worldwide after COVID-19, ischaemic heart disease, and neonatal disorders.
The burden of stroke is increasing in large part due to both population growth and the rise of aging populations worldwide, but also due to increasing contributions from preventable environmental, metabolic, and behavioural risk factors. Between 1990 and 2021, the global stroke burden linked to high body mass index (BMI; up by 88%), high temperatures (up 72%), high blood sugar (up 32%), diet high in sugar-sweetened drinks (up 23%), low physical activity (up 11%), high systolic blood pressure (up 7%), and diet low in omega-6 polyunsaturated fatty acids (up 5%) increased substantially.
However, if the impact of demographics is removed through age-standardisation (to allow comparisons between countries and over time), there has been a trend towards lower rates (age-standardised per 100,000 population) of incidence (down by 22%), prevalence (down 8%), deaths (down 39%), and DALYs (down 39%) worldwide, and across virtually all country income levels, since 1990. But since 2015, improvements in global incidence rates have stagnated, while age-standardised rates of stroke incidence, death, prevalence and DALYs have got worse in Southeast Asia, East Asia, Oceania, and in people younger than 70 years.
Lead author Professor Valery L Feigin from Auckland University of Technology, New Zealand, an affiliate professor at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, USA, said: “The global growth of the number of people who develop stroke, and died from or remain disabled by stroke is growing fast, strongly suggesting that currently used stroke prevention strategies are not sufficiently effective. New, proven effective population-wide and motivational individual prevention strategies that could be applied to all people at risk of having a stroke, regardless of the level of risk, as recommended in the recent Lancet Neurology Commission on Stroke [4] should be implemented across the globe urgently.”
The current study builds on previous GBD analyses [2] to provide the most up-to-date and comprehensive analysis of stroke burden and risk factor estimates in countries on a global scale between 1990 and 2021, to help guide health-planning, prevention, and resource allocation.
Fast-growing burden of uncontrolled risk factors, mostly affecting LMICs
The study reveals striking differences in the overall stroke burden (as measured by age-standardised incidence, prevalence, death and DALY rates) between world regions and national income levels in 2021. In high-income North America and Australasia, and middle-income Latin America—regions with the lowest stroke burden—the age-standardised rates of incidence and prevalence were lowest in New Zealand (67.8 and 707.4 per 100,000 people respectively), death rates lowest in Canada (20.4 per 100,000 people), and DALY rates lowest in Australia (435.0 per 100,000) in 2021.
In contrast, in the regions of low- and middle-income East and Central Asia and sub-Saharan Africa, the rates of incidence, prevalence, death and DALYs were up to 2 to 10 times higher (over 248, 1458, 190, and 4320 per 100,000 people, respectively) in 2021.
Strikingly, half of all the disability and the lives lost to stroke globally (81 million healthy years of life lost) in 2021 were the result of haemorrhagic strokes—the deadliest form, mainly due to high blood pressure—despite being around half as common as ischaemic strokes (4.1 million new haemorrhagic strokes vs 7.8 million new ischaemic strokes). Most affected were people aged 70 and younger and those living in low-income countries, where the proportion of strokes that are intracerebral haemorrhage is double that of high-income countries (37% vs 18%).
“Stroke-related health loss disproportionately impacts many of the most disadvantaged countries in Asia and sub-Saharan Africa due to the growing burden of uncontrolled risk factors, especially poorly controlled high blood pressure, and rising levels of obesity and type 2 diabetes in young adults, as well as the lack of stroke prevention and care services in these regions,” explained co-author Dr Catherine O. Johnson, Lead Research Scientist at IHME. “The shift in stroke burden towards younger populations is likely to continue unless effective preventive strategies are implemented urgently.”
Increasing impact of environmental risk factors
The study estimates that the total number of stroke-related DALYs attributable to 23 risk factors [3] globally has risen from 100 million years of healthy life lost in 1990 to 135 million in 2021—presenting a public health challenge and an opportunity for action. The largest proportions of these risk factors are found in Eastern Europe, Asia, and sub-Saharan Africa.
Metabolic risk factors—especially high BMI, high systolic blood pressure, and high LDL cholesterol—contributed to the most stroke burden across all country income levels (ranging from 66-70%) in 2021, followed by environmental risk factors collectively (i.e., air pollution, low/high ambient temperature, lead exposure) in LMICs (35-53%).
In 2021, the five leading global risk factors for stroke were high systolic blood pressure, particulate matter air pollution, smoking, high LDL cholesterol, and household air pollution, with considerable variation by age, sex, and location (see figure 2).
For the first time, the study suggests that ambient particulate matter air pollution is a top risk factor for subarachnoid haemorrhage, contributing to 14% of the death and disability caused by this serious stroke subtype, on a par with smoking (see figure 2).
In contrast, substantial progress has been made in reducing the global stroke burden from risk factors linked to poor diet, air pollution, and smoking, with health loss due to diets high in processed meat and low in vegetables declining by 40% and 30%, respectively, particulate matter air pollution by 20%, and smoking by 13%. This suggests that strategies to reduce exposure to these risk factors over the past three decades, such as clean air zones and public smoking bans, have been successful.
“With 84% of the stroke burden linked to 23 modifiable risk factors there are tremendous opportunities to alter the trajectory of stroke risk for the next generation,” said Dr Johnson. “Given that ambient air pollution is reciprocally linked with ambient temperature and climate change, the importance of urgent climate actions and measures to reduce air pollution cannot be overestimated. And with increasing exposure to risk factors such as high blood sugar and diet high in sugar-sweetened drinks, there is a critical need for interventions focused on obesity and metabolic syndromes. Identifying sustainable ways to work with communities to take action to prevent and control modifiable risk factors for stroke is essential to address this growing crisis.”
Prevention must be top priority
The authors say that by implementing and monitoring the evidence-based recommendations set out in the 2023 World Stroke Organization-Lancet Neurology Commission on stroke [4], there is an opportunity to drastically reduce the global burden of stroke in this decade and beyond, as well as improve brain health and the overall wellbeing of millions of people around the world.
As Professor Feigin explained: “Additional and more effective stroke prevention strategies, with an emphasis on population-wide measures, such as task-shifting from doctors to nurses and health volunteers, and the wider use of evidence-based mobile and telehealth platforms, along with pragmatic solutions to address the critical gaps in stroke service delivery, workforce capacity building, and epidemiological surveillance systems must be urgently implemented across all countries.”
Writing in a linked Comment, Professor Ming Liu and Associate Professor Simiao Wu from West China Hospital, Sichuan University in China (who were not involved in the study) say: “Pragmatic solutions to the enormous and increasing stroke burden include surveillance, prevention, acute care, and rehabilitation. Surveillance strategies include establishing a national-level framework for regular monitoring of stroke burden, risk factors, and health-care services via community-based surveys and health records. Artificial intelligence and mobile technologies might not only facilitate the dissemination of evidence-based health services, but also increase the number of data sources and encourage participation of multidisciplinary collaborators, potentially improving the validity and accuracy of future GBD estimates. We hope that GBD analyses will continue to provide timely health data and inform action in the battle against stroke at the global, regional, and national levels.”
NOTES TO EDITORS
The study was funded by the Bill and Melinda Gates Foundation. The paper was conducted by the GBD 2021 Stroke Collaborators and researchers at the University of Washington, Seattle, USA.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office pressoffice@lancet.com
Quotes from Authors cannot be found in the text of the Article, but have been supplied for the press release. The Comment quote is taken directly from the linked Comment.
[1] The Article's findings will be presented during the 16th World Stroke Congress in Abu Dabi, UAE to be held on October 23-26, 2024, Abstract Number 1482. The conference is open to registered delegates and media. Full program details are available here: https://worldstrokecongress.org/scientific-program/
[2] Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 - The Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00252-0/fulltext
[3] The risks included in the analysis were: (1) ambient particulate matter pollution; (2) household air pollution from solid fuels; (3) low temperature (daily temperatures below the TMREL); (4) high temperature (daily temperatures above the TMREL); (5) lead exposure; (6) diet high in sodium; (7) diet high in red meat; (8) diet high in processed meat; (9) diet low in fruits; (10) diet low in vegetables; (11) diet low in whole grains; (12) alcohol use (any alcohol dosage consumption); (13) diet high in sugar sweetened beverages; (14) diet low in fibre; (15) diet low in polyunsaturated fatty acids; (16) low physical activity (only for ischaemic stroke burden); (17) smoking; (18) second-hand smoke; (19) high BMI; (20) high fasting plasma glucose; (21) high systolic blood pressure; (22) high LDL cholesterol (only for ischaemic stroke burden); and (23) kidney dysfunction, as measured by low glomerular filtration rate (GFR; not assessed for subarachnoid haemorrhage burden).
[4] Pragmatic solutions to reduce the global burden of stroke: a World Stroke Organization–Lancet Neurology Commission - The Lancet Neurology
Additional key findings include:
- Age-standardised stroke incidence was lowest in Luxemburg (58 per 100,000 population) and highest in the Solomon Islands (355 per 100,000).
- Age-standardised stroke prevalence was lowest in Cyprus (522 per 100,000 population) and highest in Ghana (2,046 per 100,000).
- The rate of people who die from stroke (age-standardised per 100,000 population) was lowest in Singapore (14 per 100,000) and highest in North Macedonia (277 per 100,000).
- Age-standardised DALY rates were lowest in Switzerland (333 per 100,000 population) and highest in Nauru (6,100 per100,000).
Journal
The Lancet Neurology
Method of Research
Computational simulation/modeling
Subject of Research
People
Article Title
Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021
Article Publication Date
18-Sep-2024
COI Statement
A Abdelalim reports a leadership or fiduciary role in the Middle East and North Africa Stroke Organization, unpaid, as Vice President, outside the submitted work. S Afzal reports support for the present manuscript from King Edward Medical University through the provision of study material, research articles, valid data sources and authentic real time information for this manuscript; payment or honoraria for educational events and webinars with King Edward Medical University and collaborative partners including University of Johns Hopkins, University of California, University of Massachusetts, KEMCAANA, and KEMCA_ UK; participation on a Data Safety Monitoring Board or Advisory Board with the National Bioethics Committee Pakistan, the King Edward Medical University Ethical Review Board, the Ethical Review Board of Fatima Jinnah Medical University and Sir Ganga Ram Hospital, and being a member of the Technical Working Group on Infectious Diseases; other financial and non-financial interests in King Edward Medical University, Annals of King Edward Medical University, Quality Enhancement Cell King Edward Medical University, Faculty of Public Health United Kingdom, Scientific Session, KEMCA-UK, International Scientific Conference, KEMCAANA, Research and Publications Higher Education Commission Pakistan, Research and Journals Committee Pakistan, Medical and Dental Council Pakistan, National Bioethics Committee Pakistan, Corona Experts Advisory Group, Technical Working Group on Infectious Diseases, Dengue Experts Advisory Group, Punjab Residency Program Research Committee, all outside the submitted work. R Akinyemi reports grants U19AG074865, U19 AG076581and R01AG072547 from the US National Institutes of Health/ National Institute of Aging, GBHI ALZ UK-21- 24204 from the Alzheimer’s Association and the Global Brain Health Institute, UK Royal Society/African Academy of Sciences FLAIR Grants FLR/ R1/191813 and FCG/R1/201034, and GCRF Networking Grant from the UK Academy of Medical Sciences, all outside the submitted work. A Al-Ibraheem reports grants or contracts and support for attending meetings and/or travel from King Hussein Cancer Center, International Atomic Energy Agency; consulting fees from University of Jordan; leadership or fiduciary role, paid or unpaid, with Arab Society of Nuclear Medicine, and Asia Oceania Federation of Nuclear medicine and biology; all outside the submitted work. R Ancuceanu reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AbbVie, Laropharm, and Reckitt, outside the submitted work. J Ärnlöv reports payment or honoraria for lectures from AstraZeneca and Novartis; participation on an Advisory Board with AstraZeneca and Astella; all outside the submitted work. M Ausloos reports grants or contracts from the project “A better understanding of socio-economic systems using quantitative methods from Physics” funded by European Union – NextgenerationEU and Romanian Government, under National Recovery and Resilience Plan for Romania, contract no.760034/ 23.05.2023, cod PNRR-C9-I8-CF 255/ 29.11.2022, through the Romanian Ministry of Research, Innovation and Digitalization, within Component 9, Investment I8, outside the submitted work. O C Baltatu reports grants or contracts from National Council for Scientific and Technological Development (CNPq, 304224/2022-7) and the Anima Institute through an AI research professor fellowship; leadership or fiduciary role, paid or unpaid, with Health and Biotechnology Advisory Board at Technology Park São José dos Campos – Center for Innovation in Health Technologies (CITS), outside the submitted work. T W Bärnighausen reports grants or contracts from National Institutes of Health, Alexander von Humboldt Foundation, German National Research Foundation (DFG), European Union, German Ministry of Education and Research, German Ministry of the Environment, Wellcome, and KfW; payment or honoraria for serving as Editor-in-Chief of PLOS Medicine; participation on a Data Safety Monitoring Board or Advisory Board, unpaid, with NIH-funded research projects in Africa on Climate Change and Health; stocks in CHEERS, an SME focusing on approaches to measure climate change and health-related variables in population cohorts; all outside the submitted work. S Bhaskar reports grants or contracts from Japan Society for the Promotion of Science (JSPS), Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) through Grant-in-Aid for Scientific Research (KAKENHI), and from JSPS and the Australian Academy of Science through the JSPS International Fellowship; leadership or fiduciary role, paid or unpaid, with National Cerebral and Cardiovascular Center, Suita, Osaka, Japan, NSW Brain Clot Bank, Sydney, Australia, Rotary District 9675, Sydney, NSW, Australia, Global Health & Migration Hub Community, Global Health Hub Germany, Berlin, Germany, PLOS One, BMC Neurology, Frontiers in Neurology, Frontiers in Stroke, Frontiers in Aging, Frontiers in Public Health & BMC Medical Research Methodology, College of Reviewers, Canadian Institutes of Health Research (CIHR), Government of Canada, Cardiff University Biobank, Cardiff, UK, Cariplo Foundation, Milan, Italy, Pandemic Health System REsilience PROGRAM (REPROGRAM) Consortium; all outside the submitted work. B Bikbov reports grants or contracts with European Commission, Politecnico di Milano, and University of Rome; support for attending meetings and/or travel from European Renal Association; leadership or fiduciary role, unpaid, with Advocacy Group, International Society of Nephrology and Western Europe Regional Board, International Society of Nephrology; other non-financial in Scientific-Tools.org; all outside the submitted work. A Biswas reports consulting fees from Lupin Pharmaceuticals India, Intas Pharmaceuticals India, Alkem Laboratories India, and Eisai Pharmaceuticals India, all outside the submitted work. E J Boyko reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan), American Diabetes Association, and the International Society for the Diabetic Foot; support for attending meetings and/or travel from Korean Diabetes Association, Diabetes Association of the R.O.C. (Taiwan), and International Society for the Diabetic Foot; all outside the submitted work. A L Catapano reports grants or contracts from Amryt Pharma, Menarini, and Ultragenyx; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amarin, Amgen, Amryt Pharma, AstraZeneca, Daiichi Sankyo Esperion Ionis Pharmaceutical Medscaper, Menarini, Merck, Novartis, NovoNordisk, Peervoice Pfizer Recordati Regeneron, Sandoz, Sanofi The Corpus, Ultragenyx, and Viatris; all outside the submitted work. S Das reports a leadership or fiduciary role, unpaid, with association of Diagnostic & Laboratory Medicine India Chapter and Women in Global Health India, outside the submitted work. A Demetriades reports Leadership or fiduciary role, paid or unpaid as the Immediate Past President, European Association of Neurosurgical Societies (EANS) and Vice-President, Global Neuro Foundation, outside the submitted work. A Faro reports support for the present manuscript from National Council for Scientific and Technological Development (CNPq) through a scholarship. M Foschi reports consulting fees from Novartis and Roche; support for attending meetings and/or travel from Roche, Novartis, Biogen, Bristol-Meyer, Merck, and Sanofi; leadership or fiduciary role with MSBase Foundation as a member of the scientific leadership group; all outside the submitted work. R Franklin reports support for attending meetings and/or travel from ACTM – Tropical Medicine and Travel Medicine Conference 2022, 2023 and ISTM – Travel Medicine Conference, Basel 2023; leadership or fiduciary role, paid or unpaid, as Director of Kidsafe, Director of Auschem, Governance Committee of ISASH, Director of Farmsafe, SIG Convenor of PHAA Injury Prevention, and Vice President of ACTM; all outside the submitted work. A Guha reports grants or contracts from American Heart Association and Department of Defense; consulting fees from Pfizer and Novartis; leadership or fiduciary role, paid or unpaid, with ZERO Prostate Cancer – health equity task force; all outside the submitted work. G J Hankey reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from American Heart Association (for serving as Associate Editor of Circulation) Janssen (Johnson & Johnson) (for serving as Co-chair of Executive Committee, Librexia Stroke Trial, and lectures at sponsored scientific symposia), outside the submitted work. N E Ismail reports leadership or fiduciary role, unpaid, with Malaysian Academy of Pharmacy, Malaysia, and Malaysian Pharmacists Society Education Chapter, Malaysia, all outside the submitted work. T Joo reports support for the present manuscript from National Research, Development and Innovation Office in Hungary (RRF-2.3.1-21-2022-00006, Data-Driven Health Division of National Laboratory for Health Security) for funding of participation in the research project. J J Jozwiak reports Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, ADAMED, and Amgen; outside the submitted work. K Krishan reports non-financial support from the UGC Centre of Advanced Study, CAS II, awarded to the Department of Anthropology, Panjab University, Chandigarh, India, outside the submitted work. B Lacey reports support for the present manuscript from UK Biobank, funded largely by the UK Medical Research Council and Wellcome. P M Lavados reports grants from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim for LATAM Stroke Projects Mentorship; payment or honoraria for lectures from Boehringer Ingelheim, Ferrer, Pfizer, and Novartis; support for attending Southamerican Angels meetings from Boehringer Ingelheim; participation on a Data Safety Monitoring Board or Advisory Board with Janssen, BMS, and Pfizer; leadership or fiduciary role, paid or unpaid, with Chilean Stroke Association (ACEVE) and Iberoamerican Stroke Society (SIECV-IASO); all outside the submitted work. M Li reports grants or contracts from the National Science and Technology Council, Taiwan (NSTC 112-2410-H-003-031; leadership or fiduciary role, paid or unpaid, as Technical Editor, Journal of the American Heart Association; all outside the submitted work. D Lindholm reports previous stock options and other financial or non-financial interests in AstraZeneca as a former employee, outside the submitted work. W Lo report stock or stock options in Abbott Lab, Amgen, Becton Dickson, Bristol Myers Squibb, Cardinal Health, GE Healthcare, Illumina, McKesson, Merck, Moderna, Pfizer, and Walgreens Boots, outside the submitted work. S Lorkowski reports grants or contracts from dsm-firmenich (formerly DSM Nutritional Products) as payments to their institution; consulting fees from Danone, Novartis Pharma, and Swedish Orphan Biovitrum (SOBI); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AMARIN Germany, Amedes Holding, Amgen, Berlin-Chemie, Boehringer Ingelheim Pharma, Daiichi Sankyo Deutschland, Danone, Hubert Burda Media Holding, Janssen-Cilag, Lilly Deutschland, Novartis Pharma, Novo Nordisk Pharma, Roche Pharma, Sanofi-Aventis, Swedish Orphan Biovitrum (SOBI), SYNLAB Holding Deutschland; support for attending meetings and/or travel from AMGEN; participation on a Data Safety Monitoring Board or Advisory Board from AMGEN, Daiichi Sankyo Deutschland, Novartis Pharma, Sanofi-Aventis; all outside the submitted work. L G Manotvani reports support for the present manuscript from the Italian Ministry of Health, Ministero della Salute, Ricerca Corrente, IRCCS Istituto Auxologico Italiano.H R Marateb reports support for their participation in present manuscript from Beatriu de Pinós postdoctoral programme from the Office of the Secretary of Universities and Research from the Ministry of Business and Knowledge of the Government of Catalonia programme: (2020 BP 00261). S Meo reports grants or contracts from Researchers Supporting Project, King Saud University, Riyadh, Saudi Arabia (RSP-2024 R47), outside the submitted work. L Monasta reports support for the present manuscript from the Italian Ministry of Health (Ricerca Corrente 34/2017), payments made to the Institute for Maternal and Child Health IRCCS Burlo Garofolo. R Moreira reports grants or contracts from CNPq (National Council for Scientific and Technological Development, scholarship registration number 316607/2021-5) outside the submitted work. S Muthu reports receiving the Luiz Vialle Award 2024 for travel support to attend Global Spine Congress 2024 from AO Spine International; leadership or fiduciary role with SICOT Awards Committee, AO Spine Associate Knowledge Forum, ICRS Next-Gen Committee; all outside the submitted work. S Nomura reports grants from Ministry of Education, Culture, Sports, Science and Technology of Japan (21H03203), and Precursory Research for Embryonic Science and Technology from the Japan Science and Technology Agency (JPMJPR22R8); outside the submitted work. B Norrving reports participation on a data safety or monitoring board or advisory board with Simbec-Orion (HOVID Trial); outside the submitted work. A Oneil reports grants or contracts from the National Health and Medical Research Council via her institution (#2009295); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from the Exercise & Sports Science Australia conference for an invited presentation; outside the submitted work. A P Okekunle reports support for the present manuscript from National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265); support for attending meetings and/or travel from National Research Foundation of Korea funded by the Ministry of Science and ICT (2020H1D3A1A04081265); all outside the submitted work. R Ornello reports institutional grants from Novartis, consulting fees from Teva; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Eli Lilly, Novartis, Pfizer, Teva, AbbVie, and Lundbeck; support for attending meetings or travel from Teva; participation on a Data Safety Monitoring Board or Advisory Board with Eli Lilly; leadership or fiduciary role with The Journal of Headache and Pain Editorial Board, and Frontiers in Neurology Headache and Neurogenic Pain Section; receipt of payment of publication fees from Novartis and AbbVie; all outside the submitted work. A Ortiz reports grants to their institute from Sanofi and Catedra Mundipharma-UAM of diabetic kidney disease and the Catedra AstraZeneca-UAM of chronic kidney disease and electrolytes; consultancy or speaker fees Advicciene , Astellas, AstraZeneca, Amicus, Amgen, Boehringer-Ingelheim, Fresenius Medical Care, GSK, Bayer, Sanofi-Genzyme, Menarini, Kyowa Kirin, Alexion, Idorsia, Chiesi, Otsuka, Novo-Nordisk and Vifor Fresenius Medical Care Renal Pharma; travel support from Advicciene , Astellas, AstraZeneca, Fresenius Medical Care, Boehringer-Ingelheim Bayer, Sanofi-Genzyme, Menarini, Chiesi, Otsuka, Sysmex; leadership or fiduciary role, unpaid, with Council ERA. SOMANE; all outside the submitted work. E Ortiz-Prado reports grants or contracts from Universidad de las Americas, QuitoEcuador outside the submitted work. R Palma-Alvarez reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Angelini, Casen Recordarti, Lundbeck, Rubió, Takeda, Servier, and Neuraxpharm; support for attending meetings or travel from Angelini, Casen Recordati, Takeda, Italfarmaco, Lundbeck, and Janssen; all outside the submitted work. R Passera reports participation on Data Safety Monitoring Board dello studio “Consolidation with ADCT-402 (loncastuximab tesirine) after immunochemotherapy: a phase II study in BTKi-treated/ineligible Relapse/Refractory Mantle Cell Lymphoma (MCL) patients” - FIL, Fondazione Italiana Linfomi, Alessandria; leadership or fiduciary role, unpaid, as a Member of the EBMT Statistical Committee, European Society for Blood and Marrow Transplantation, Paris (F), and Past member 2020-2023 (biostatistician) of the IRB/IEC Comitato Etico AO SS. Antonio e Biagio Alessandria-ASL AL-VC; all outside the submitted work. A E Peden reports support for the present manuscript from [Australian] National Health and Medical Research Council (Grant Number: APP2009306). A Rane reports being a full-time employee of Agios Pharmaceuticals and owning stock and stock options, outside the submitted work. S Sacco reports grants or contracts from Novartis and Uriach; consulting fees from Novartis, Allergan-AbbVie, Teva, Lilly, Lundbeck, Pfizer, NovoNordisk, Abbott, and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis, Allergan-Abbvie, Teva, Lilly, Lundbeck, Pfizer, NovoNordisk, Abbott, AstraZeneca; support for attending meetings and/or travel Lilly, Novartis, Teva, Lundbeck, and Pfizer; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with President European Stroke Organisation, and as Editor-in-Chief Cephalalgia; receipt of equipment, materials, drugs, medical writing, gifts or other services from AllerganAbbVie, NovoNordisk; all outside the submitted work. Y L Samodra reports grants or contracts from FK Unpar, Indonesia; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with Benang Merah Research Center, Indonesia; all outside the submitted work. J Sanabria reports support for attending meetings and/or travel from Continuous Medical Education (CME) funds from Marshall University School of Medicine; participation on a Data Safety Monitoring Board or Advisory Board with Quality officer for the Department of Surgery; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with SSAT, ACS, IHPBA, American Board of Surgery; all outside the submitted work. N Scarmeas reports grants or contracts from Novo Nordisk through funding to their institution; participation on a Data Safety Monitoring Board or Advisory Board with the Multicultural Healthy Diet to Reduce Cognitive Decline & AD Risk NIH Funded Study at Albert Einstein College of Medicine, and with Primus AD through a Public Private funded Phase II study in Germany; all outside the submitted work. B M Schaarschmidt reports grants from Else Kröner-Fresenius Foundation, Deutsche Forschungsgemeinschaft, and PharmaCept; payment or honoraria for lectures from AstraZeneca; support for travel from Bayer AG; all outside the submitted work. A E Schutte reportsgrants or contracts from National Health and Medical Research Council of Australia, and the Medical Research Future Fund, Australia; consulting fees from Skylabs, Abbott, and Servier; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Abbott, Servier, Sanofi, Omron, Medtronic, and Aktiia; support for attending meetings or travel from Medtronic and Servier; leadership or fiduciary role, paid or unpaid, as Co-Chair National Hypertension Taskforce of Australia; all outside the submitted work. A Sharifan reports Leadership or fiduciary role, unpaid, with Cochrane Early Career Professionals Network; receipt of equipment, materials, drugs, medical writing, gifts or other services from Elsevier and Cochrane; all outside the submitted work. V Sharma reports other financial or non-financial interests in DFSS (MHA)’s research project (DFSS28(1)2019/EMR/6) at Institute of Forensic Science & Criminology, Panjab University, Chandigarh, India, outside the submitted work. S Shrestha reports other financial or non-financial interests in the School of Pharmacy, Monash University Malaysia, and the Graduate Research Merit Scholarship, outside the submitted work. J Silva reports support for the present manuscript from Portuguese Foundation for Science and Technology through salary payments (contract with reference 2021.01789.CEECIND/CP1662/CT0014). L R Silva reports grants or contracts from project code CENTRO-04-3559-FSE-000162, Fundo Social Europeu (FSE), outside the submitted work. J A Singh reports consulting fees from ROMTech, Atheneum, Clearview healthcare partners, American College of Rheumatology, Yale, Hulio, Horizon Pharmaceuticals, DINORA, Frictionless Solutions, Schipher, Crealta/ Horizon, Medisys, Fidia, PK Med, Two labs, Adept Field Solutions, Clinical Care options, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events on the speakers bureau of Simply Speaking; Support for attending meetings and/or travel from OMERACT as a steering committee member; Participation on a Data Safety Monitoring Board or Advisory Board with the FDA Arthritis Advisory Committee; Leadership or fiduciary role in other board, society, committee or advocacy group, paid as a past steering committee member of the OMERACT, an international organisation that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies, unpaid as Chair of the Veterans Affairs Rheumatology Field Advisory Committee, and unpaid as the Editor and Director of the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis; stock or stock options in Atai life sciences, Kintara therapeutics, Intelligent Biosolutions, Acumen pharmaceutical, TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., Aebona Pharmaceuticals, and Charlotte’s Web Holdings, Inc. and previously owned stock options in Amarin, Viking, and Moderna Pharmaceuticals; all outside the submitted work. J Sipila reports grants or contracts from Siun Sote Foundation and Eemil Aaltonen Foundation; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Novartis; support for attending meetings and/or travel from Lundbeck; participation on a Data Safety Monitoring Board or Advisory Board with Boehringer-Ingelheim and Sandoz; stock or stock options in Orion Corp; all outside the submitted work. J Sundstrom reports direct or indirect stock ownership in companies (Anagram kommunikation AB, Sence Research AB, Symptoms Europe AB, MinForskning AB) providing services to companies and authorities in the health sector including Amgen, AstraZeneca, Bayer, Boehringer, Eli Lilly, Gilead, GSK, Göteborg University, Itrim, Ipsen, Janssen, Karolinska Institutet, LIF, Linköping University, Novo Nordisk, Parexel, Pfizer, Region Stockholm, Region Uppsala, Sanofi, STRAMA, Takeda, TLV, Uppsala University, Vifor Pharma, WeMind, all outside the submitted work. A G Thrift reports grants or contracts from National Health & Medical Research Council (Australia), Heart Foundation (Australia), and Stroke Foundation (Australia); outside the submitted work. J H V Ticolau reports leadership or fiduciary role, paid or unpaid, with Benang Merah Research Center, Indonesia, outside the submitted work. S J Tromans reports grants or contracts from NHS Digital, via the Department of Health and Social Care, as payments to their institution; leadership or fiduciary role, unpaid, with the Academic Secretary for the Neurodevelopmental Psychiatry Special Interest Group at the Royal College of Psychiatrists, Editorial Board for BMC Psychiatry, Advances in Autism, Advances in Mental Health and Intellectual Disability, and Progress in Neurology and Psychiatry; all outside the submitted work. P Willeit reports consulting fees from Novartis Pharmaceuticals, outside the submitted work. Y Yasufuku reports grants or contracts from Shionogi & Co, through funding to their institution, outside the submitted work. M Zielinska reports other financial or non-financial interests in AstraZeneca as an employee, outside the submitted work.